Drug Profile
Sarilumab - Regeneron/Sanofi
Alternative Names: Anti-IL 6 receptor antibody; Anti-interleukin 6 receptor antibody; Kevzara; REGN-88; SAR-153191Latest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals; sanofi-aventis
- Developer Asahi Kasei Pharma Corp; Regeneron Pharmaceuticals; Sanofi
- Class Anti-inflammatories; Antirheumatics; Antivirals; Monoclonal antibodies
- Mechanism of Action Interleukin 6 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Rheumatoid arthritis
- Registered Polymyalgia rheumatica
- Preregistration Juvenile rheumatoid arthritis
- Discontinued Ankylosing spondylitis; COVID 2019 infections; Giant cell arteritis; Uveitis
Most Recent Events
- 19 Feb 2024 Sanofi announces intention to submit a regulatory application for Juvenile rheumatoid arthritis (Sanofi pipeline, February 2024)
- 01 Feb 2024 FDA assigns PDUFA action date of 10/06/2024 for review of sBLA of Sarilumab for Juvenile rheumatoid arthritis
- 01 Feb 2024 Sanofi plans regulatory submission for approval of Sarilumab for the treatment of children and adolescents with juvenile rheumatoid arthritis in 2027 in EU and ROW